Latest News and Press Releases
Want to stay updated on the latest news?
-
For release content, please refer to the attachment....
-
For release content, please refer to the attachment....
-
Händelser under januari - juni, 2013: Laquinimod · positiva resultat från fas IIa-studie av laquinimod i aktiv lupus nefrit· Teva planerar fortsatt klinisk utveckling av laquinimod för behandling av...
-
Events during January - June 2013: Laquinimod · positive results from Phase IIa study of laquinimod in active lupus nephritis· Teva plans continued clinical development of laquinimod for the...
-
· Laquinimod i kombination med standardbehandling uppvisar additiv effekt på förbättring av njurfunktion · Resultaten ger stöd för vidare studier av laquinimod i aktiv lupus nefrit...
-
· Laquinimod showed additive effect in improving renal function when combined with the standard of care treatment · Results provide rationale for further studies of laquinimod in...
-
Tasquinimod Phase II retrospective follow-up study shows an impact of tasquinimod on bone metastases as measured by Bone Scan Index (BSI) Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX...
-
Fas II/III-data gällande överlevnad och tid till sjukdomsförsämring presenteras på konferensen 2013 ASCO Annual Meeting Lund den 3 juni 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) har idag på...
-
Tasquinimod fas II uppföljningsstudie och mätning enligt Bone Scan Index (BSI) visar att tasquinimod hämmar skelettmetastaser Lund, Sverige den 3 juni, 2013. Active Biotech (NASDAQ OMX NORDIC:...
-
Phase II/III Overall Survival and PFS data presented at the 2013 ASCO Annual Meeting Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented overall survival (OS)...